Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Female
Follow-Up Studies
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Male
Maximum Tolerated Dose
Melanoma
/ drug therapy
Middle Aged
Neoplasm Metastasis
Prognosis
Protein Kinase C
/ antagonists & inhibitors
Pyrroles
/ pharmacokinetics
Quinazolines
/ pharmacokinetics
Tissue Distribution
Uveal Neoplasms
/ drug therapy
Young Adult
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
28
01
2019
revised:
24
04
2019
accepted:
23
01
2020
pubmed:
8
2
2020
medline:
7
4
2021
entrez:
8
2
2020
Statut:
ppublish
Résumé
Up to 50% of patients with uveal melanoma (UM) develop metastatic disease, for which there is no effective systemic treatment. This study aimed to evaluate the safety and efficacy of the orally available protein kinase C inhibitor, AEB071, in patients with metastatic UM, and to perform genomic profiling of metastatic tumor samples, with the aim to propose combination therapies. Patients with metastatic UM (
Identifiants
pubmed: 32029634
pii: 1535-7163.MCT-19-0098
doi: 10.1158/1535-7163.MCT-19-0098
doi:
Substances chimiques
Biomarkers, Tumor
0
Pyrroles
0
Quinazolines
0
sotrastaurin
7I279E1NZ8
Protein Kinase C
EC 2.7.11.13
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1031-1039Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
©2020 American Association for Cancer Research.